FDAnews
www.fdanews.com/articles/81719-inovio-publishes-study-results-of-hiv-and-vascular-disease-therapies

INOVIO PUBLISHES STUDY RESULTS OF HIV AND VASCULAR DISEASE THERAPIES

October 17, 2005

Inovio Biomedical has announced that two articles presenting study results relating to gene-based therapies for HIV and vascular disease were published in peer-reviewed scientific journals in September. These articles were jointly published with Inovio's collaborators, Chiron and Boehringer Ingelheim, respectively.

The first article, entitled "Potent immunogenicity of an HIV-1 gag-pol fusion DNA vaccine delivered by in vivo electroporation," was published jointly by Chiron and Genetronics, in the journal, Vaccine. The article reported results of a preclinical study of a plasmid DNA vaccine containing an HIV-derived gag-pol fusion gene delivered intramuscularly in non-human primates by Inovio's electroporation technology. The article concluded that this approach was an effective means for inducing high levels of gag and pol-specific T-cells.

A second article, entitled "In vivo human MCP-1 transfection in porcine arteries by intravascular electroporation," was published in Pharmaceutical Research. This article reported the efficient delivery of an arteriogenic gene (a gene inducing small vessels to develop into sizeable arteries) into the wall of a blocked artery and concluded that transluminal catheter-based electroporation provides an efficient technology for non-viral intravascular gene transfer.